Bibliometric and visual analysis of miRNAs in heart diseases from 2004 to 2023 DOI Creative Commons
Ying Jin,

Jingqi Duan,

Qiaoxiang Yin

и другие.

Frontiers in Cardiovascular Medicine, Год журнала: 2025, Номер 12

Опубликована: Март 20, 2025

Background MicroRNAs (miRNAs) add a new dimension to HD forecast, diagnosis, and therapy based on the potential applications. The miRNA-related research in heart disease (HD) field has received close attention past two decades. However, there is lack of studies that comprehensively objectively analyze current situation miRNA application using bibliometrics method. Objective To global scientific outputs miRNAs from 2004 2023. Methods All articles reviews were retrieved Web Science core collection (WOSCC) title search, bibliometric analysis was performed Microsoft Excel 2019, CiteSpace, VOSviewer, Bibliometrics (R-Tool R-Studio). Results 3,874 publications included analysis. Collaborative network indicates China with maximum number (2,063) USA highest total citations (59,331) are influential countries this field. Peking Union Medical College most prolific university (134), University California System authoritative institution regarding betweenness centrality (0.27). PLOS ONE tops journal list publications, closely followed by International Journal Molecular Sciences Scientific Reports more than 100 articles. Considering citations, link strength overall, Olson. Eric N, Van Rooij Eva, Thum Thomas, Yang Baofeng, Wang Kun; Lu Yanjie authors expression changes regulatory mechanisms specific various biological pathophysiological processes have been continuous hotspots. “exosomes”, “extracellular vesicles”, “autophagy”, “management” novel hot topics since 2018, which focused diagnosis treatment HD. development trend how translate achievement therapeutic drugs for into clinic. Conclusion Our study revealed intellectual structure research, may help scholars understand find partners.

Язык: Английский

miRNAs orchestration of gallbladder cancer – Particular emphasis on diagnosis, progression and drug resistance DOI

Reem K. Shahin,

Mohamed A. Elkady, Ahmed I. Abulsoud

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 248, С. 154684 - 154684

Опубликована: Июль 13, 2023

Язык: Английский

Процитировано

34

Decoding the role of miRNAs in multiple myeloma pathogenesis: A focus on signaling pathways DOI

Amr Mohamed Yehia,

Elsayed G.E. Elsakka, Ahmed I. Abulsoud

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 248, С. 154715 - 154715

Опубликована: Июль 27, 2023

Язык: Английский

Процитировано

32

The potential role of miRNAs in the pathogenesis of gallbladder cancer – A focus on signaling pathways interplay DOI
Ahmed S. Doghish,

Heba M. Midan,

Abdullah M. M. Elbadry

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 248, С. 154682 - 154682

Опубликована: Июль 11, 2023

Язык: Английский

Процитировано

29

miRNAs orchestration of adrenocortical carcinoma - Particular emphasis on diagnosis, progression and drug resistance DOI
Walaa A. El‐Dakroury,

Heba M. Midan,

Ahmed I. Abulsoud

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 248, С. 154665 - 154665

Опубликована: Июль 4, 2023

Язык: Английский

Процитировано

28

miRNAs driving diagnosis, progression, and drug resistance in multiple myeloma DOI
Mohamed A. Elkady,

Amr Mohamed Yehia,

Elsayed G.E. Elsakka

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 248, С. 154704 - 154704

Опубликована: Июль 22, 2023

Язык: Английский

Процитировано

28

The potential role of miRNAs in the pathogenesis of adrenocortical carcinoma – A focus on signaling pathways interplay DOI

Heba M. Midan,

Gouda K. Helal,

Ahmed I. Abulsoud

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 248, С. 154690 - 154690

Опубликована: Июль 17, 2023

Язык: Английский

Процитировано

24

The emerging role of miRNAs in Merkel cell carcinoma pathogenesis: Signaling pathway crosstalk DOI

Nehal I. Rizk,

Heba M. Midan,

Gouda K. Helal

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 249, С. 154771 - 154771

Опубликована: Авг. 19, 2023

Язык: Английский

Процитировано

24

Melodic maestros: Unraveling the role of miRNAs in the diagnosis, progression, and drug resistance of malignant pleural mesothelioma DOI

Mai A. Abd‐Elmawla,

Sherif S. Abdel Mageed, Tohada M. AL‐Noshokaty

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 250, С. 154817 - 154817

Опубликована: Сен. 13, 2023

Язык: Английский

Процитировано

24

Unraveling the role of miRNAs in the diagnosis, progression, and therapeutic intervention of Alzheimer’s disease DOI
Nourhan M. Abdelmaksoud, Al-Aliaa M. Sallam, Ahmed I. Abulsoud

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155007 - 155007

Опубликована: Дек. 4, 2023

Язык: Английский

Процитировано

23

Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics DOI Creative Commons
Paula Gil-Cabrerizo, Teresa Simón‐Yarza, Elisa Garbayo

и другие.

Advanced Drug Delivery Reviews, Год журнала: 2024, Номер 208, С. 115302 - 115302

Опубликована: Апрель 3, 2024

Cardiovascular diseases (CVDs) stand as the leading cause of death worldwide, posing a significant global health challenge. Consequently, development innovative therapeutic strategies to enhance CVDs treatment is imperative. RNA-based therapies, encompassing non-coding RNAs, mRNA, aptamers, and CRISPR/Cas9 technology, have emerged promising tools for addressing CVDs. However, inherent challenges associated with RNA, such poor cellular uptake, susceptibility RNase degradation, capture by reticuloendothelial system, underscore necessity combining these therapies effective drug delivery systems. Various non-viral systems, including extracellular vesicles, lipid-based carriers, polymeric inorganic nanoparticles, well hydrogels, shown promise in enhancing efficacy RNA therapeutics. In this review, we offer an overview most relevant explored emphasize pivotal role systems augmenting their effectiveness. Additionally, discuss current status that hinder clinical translation.

Язык: Английский

Процитировано

10